ARCA biopharma to Present at the Q3 Virtual Investor Summit on August 18th
16 août 2021 08h05 HE
|
ARCA biopharma, Inc.
WESTMINSTER, Colo., Aug. 16, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted...
Christopher Graybill Joins ARCA as Vice President, Clinical Development
05 mai 2021 16h05 HE
|
ARCA biopharma, Inc.
WESTMINSTER, Colo., May 05, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted...
ARCA Biopharma Announces First Quarter 2020 Financial Results And Provides Corporate Update
06 mai 2020 16h30 HE
|
ARCA biopharma, Inc.
U.S. FDA Special Protocol Assessment agreement for PRECISION-AF, a single pivotal Phase 3 clinical trial of genetically targeted GencaroPRECISION-AF trial to evaluate Gencaro as a potential treatment...
ARCA biopharma Announces Second Quarter 2019 Financial Results and Provides Corporate Update
01 août 2019 16h30 HE
|
ARCA biopharma, Inc.
FDA SPA Agreement for Phase 3 atrial fibrillation trial (PRECISION-AF) amended to expand patient population to include heart failure patients with preserved ejection fraction (HFpEF)PRECISION-AF...
ARCA Biopharma Announces First Quarter 2019 Financial Results and Provides Corporate Update
08 mai 2019 16h30 HE
|
ARCA biopharma, Inc.
WESTMINSTER, Colo., May 08, 2019 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted...
Identification of Phosphodiesterease 3A Polymorphism With Potential to Increase Effectiveness of PDE3 Inhibitors Published in the Journal of the American College of Cardiology
18 mars 2019 08h30 HE
|
ARCA biopharma, Inc.
WESTMINSTER, Colo., March 18, 2019 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted...
ARCA biopharma Announces Fiscal Year 2018 Financial Results and Provides Corporate Update
27 févr. 2019 16h15 HE
|
ARCA biopharma, Inc.
WESTMINSTER, Colo., Feb. 27, 2019 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted...
GENETIC-AF Phase 2B Clinical Trial Atrial Fibrillation Burden (AFB) Results Presented at American Heart Association 2018 Scientific Sessions
12 nov. 2018 08h30 HE
|
ARCA biopharma, Inc.
AF detection by implanted Medtronic devicesSimilar trends for benefit in favor of Gencaro compared to active comparator for AF risk reduction observed by continuous monitoring with implanted devices...
ARCA Biopharma announces first quarter 2018 financial results AND Provides Corporate Update
08 mai 2018 16h15 HE
|
ARCA biopharma, Inc.
WESTMINSTER, Colo., May 08, 2018 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted...
ARCA biopharma Announces Completion of GENETIC-AF Phase 2B Clinical Trial
08 janv. 2018 08h30 HE
|
ARCA biopharma, Inc.
-------------------------------------------------------------------------------------------------- GENETIC-AF Evaluating Gencaro as Potentially First Genetically-Targeted Treatment for Atrial...